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Abstract
Background: Computer-aided drug design has a long history of being applied to discover new molecules to treat
various cancers, but it has always been focused on single targets. The development of systems biology has let
scientists reveal more hidden mechanisms of cancers, but attempts to apply systems biology to cancer therapies
remain at preliminary stages. Our lab has successfully developed various systems biology models for several cancers.
Based on these achievements, we present the first attempt to combine multiple-target therapy with systems biology.
Methods: In our previous study, we identified 28 significant proteins–i.e., common core network markers–of four
types of cancers as house-keeping proteins of these cancers. In this study, we ranked these proteins by summing
their carcinogenesis relevance values (CRVs) across the four cancers, and then performed docking and
pharmacophore modeling to do virtual screening on the NCI database for anti-cancer drugs. We also performed
pathway analysis on these proteins using Panther and MetaCore to reveal more mechanisms of these cancer
house-keeping proteins.
Results: We designed several approaches to discover targets for multiple-target cocktail therapies. In the first one,
we identified the top 20 drugs for each of the 28 cancer house-keeping proteins, and analyzed the docking pose
to further understand the interaction mechanisms of these drugs. After screening for duplicates, we found that 13
of these drugs could target 11 proteins simultaneously. In the second approach, we chose the top 5 proteins with
the highest summed CRVs and used them as the drug targets. We built a pharmacophore and applied it to do
virtual screening against the Life-Chemical library for anti-cancer drugs. Based on these results, wet-lab bio-
scientists could freely investigate combinations of these drugs for multiple-target therapy for cancers, in contrast to
the traditional single target therapy.
Conclusions: Combination of systems biology with computer-aided drug design could help us develop novel
drug cocktails with multiple targets. We believe this will enhance the efficiency of therapeutic practice and lead to
new directions for cancer therapy.
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Background
Cancer is the leading cause of human death worldwide.
It is a complex set of diseases, and people have tried to
reveal its underlying mechanisms to guide the develop-
ment of novel therapy strategies. In the last two decades,
cancer researchers have generated an abundance of
knowledge about cancer, and revealed the etiology of
various cancers at DNA, RNA, and protein levels [1].
Weinberg et al. summarized the first and next genera-
tion of cancer hallmarks to expand the current under-
standing of the basic mechanisms of cancer [2,3].
Recently, due to the scale up in high throughput data,
availability of integrated OMICS data, and various
advanced statistical analysis methods, many novel sys-
tems biology approaches have been employed to reveal
the deeper underlying systematic mechanisms of various
cancers [4-6].
Traditional computer-aided drug design (CADD)
focuses on a single target for therapy, such as Src, FAK,
and EGFR in the case of cancer [7,8]. Researchers have
used virtual screening with de novo methods to develop
small molecules that in most cases inhibit these targets
(although sometimes they are agonists), and accordingly
reduce the expression of these proteins to kill cancer
cells. CADD has a long history and many successful
examples. CADD methods can be divided into structure-
based and ligand-based methods [9]. Methods in the for-
mer category analyze both the structures of the target
protein and the small molecule inhibitors to design
drugs: examples include the docking method and mole-
cular dynamics simulations. On the other hand, methods
in the latter category use only the structures of the small
molecule inhibitors (drugs) to do statistical calculations
to determine the relationship between a drug’s IC50 and
its corresponding molecular properties: examples include
HypoGen pharmacophore modeling, COMFA (and
COMSIA) [10], and many other machine learning and
regression methods [11,12].
One of the main differences between Western and Chi-
nese medical philosophy is that the former focuses on
single targets, while the latter focuses on multiple targets
simultaneously [13]. Systems biology reconstructs the
regulatory relationships within genetic, metabolic, and
protein-protein interaction networks. These biological
networks are highly complex, so robustness and sensitiv-
ity are their key system-level features [14,15]. The inter-
twined nature of these networks shows us that inhibiting
a single protein directly is not the only way to depress its
expression. Systems biology will helps us to identify sev-
eral protein targets to be inhibited simultaneously: due to
their network behaviour, this multi-target approach will
produce the same or better effect, than focusing on a sin-
gle target protein. Also, recent research has demonstrated
that to inhibit protein-protein interactions (PPI) is
another novel anti-cancer strategy [16]. Inspired by the
above ideas, based on the result of our previous systems
biology studies [17], we have developed a novel multi-
target cocktail therapy to focus on common core network
markers of four different cancers. Our strategy is differ-
ent from Dr. Ho’s famous cocktail therapy for AIDS [18],
which is not targeted therapy. Our method is to apply
traditional CADD methods simultaneously to multiple
drug targets. We regard this as a great advance in novel
anti-cancer strategies.
Theoretical biological background: Recently, PPI-based
analysis seems to have become a novel strategy or can-
cer target drug therapy and the development of preci-
sion medicine [16,19]. Unlike traditional target drug
design, which focuses on the inhibition or activation of
a single target protein, usually a receptor or enzyme,
PPI-based drug design involves inhibition of PPIs inter-
face that mediate many important biological processes
by small molecule; it is a novel and creative approach to
drug discovery, especially for anti-cancer. Many clinical
and elementary biological researches have concluded
that the identification of PPI nodes and hubs that are
significant for cell transformation functions in cancer.
These PPIs related to cancers have become important
targets for cancer therapy. Progress on technologies in
the identification of PPI modulators and the clinical
validation of the PPI pairs has made anti-cancer thera-
peutics by interfering with PPIs a reality [16,19].
So, to identify PPI interface and PPI targets are
regarded as the future topics for next generation antic-
ancer strategies. Nevertheless, the cancer PPI networks
are always highly complex and differ between cancer
subtypes. Hence, we put concentration on common PPI
network markers and their PPIs with a critical carcino-
genesis relevance value (CRV), which is an estimate of
the PPI evolution during the carcinogenesis process, to
focus on the conservation of house-keeping proteins
and their PPI interface characteristics as important tar-
gets shared by different cancers. This allows us to not
only find out the crucial common pathways of different
cancers in carcinogenesis, but also discover novel PPI
targets for cancer therapy. Specific network markers can
be regarded to represent specific PPI targets for each
cancer. To target PPIs in both common core network
markers and specific network markers simultaneously
may provide new directions for anticancer therapy
strategies.
Theoretical, mathematical, and statistical method: The
traditional methods to find hubs or driven proteins in
the gene regulatory or PPI networks of cancers is differ-
ent from our method. In our previous study [17], we
compared between the networks of each cancer and its
corresponding normal PPI, which were obtained by the
AIC (akaike information criterion) order detection and
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Student t-test methods from microarray expression data
of patients and normal people, respectively, to get the
PPI differential network in order to reveal PPI alterna-
tions during the tumorigenesis process. And then, we
developed a carcinogenesis relevance value (CRV) for
each protein in the PPI differential network based on
the total alternations of PPI interaction abilities with
other proteins to approve the critical PPI changes dur-
ing tumorigenesis process. In the end, we obtained the
core and specific network markers by using the intersec-
tion and difference of these 4 cancers with top CRVs.
These novel core and specific network markers could
provide possible PPI targets for small-molecule drugs to
interfere and then destroy tumors. Calculations and esti-
mations were using real microarray expression data. The
maximum likelihood parameter estimation method and
AIC model order selection method are well-known and
widely used system identification methods from experi-
mental data. During these estimation and learning pro-
cesses, the PPI interaction mathematical model can
derive the most probable PPI network for cancer and
normal patients from large amount of microarray data
and big databases to interpret the hidden biological
mechanisms. The above paragraphs are adapted from
our previous study [17] to make this paper be a com-
plete paper.
In our previous study, we analyzed various cancers–
specifically, bladder, colorectal, liver, and lung cancers–
through regression modeling, microarray data, maxi-
mum likelihood parameter estimations, and big database
mining. Based on known PPI information and gene
expression data from normal and patient samples, we
built a cancer PPI network [17]. Here, we focus on not
only the PPI networks of single cancer types but also on
common core network markers of four different cancers
through the intersection of their respective PPI net-
works. Cancer is a complex disease, and so we tried to
reveal house-keeping proteins significant in different
cancers, i.e. the common core network markers shared
by the different cancers. As the first trial to develop
multiple-target therapy, cancer house-keeping proteins
(common core network markers) may be a good choice.
There are two main parts of this research. One is to
find the core network markers of four cancers by sys-
tems biology approach, and the other is to attach these
network markers by ligand-based and structure-based
CADD (computer-aided drug design) methods. The first
part has been published on Journal of Theoretical Biol-
ogy [17]. The whole work of this research is the Part-II,
i.e., using the CADD methods to attach the network
biomarkers. To make this paper complete, so we
described how to get these network biomarkers in our
previous research [17].
Materials and methods
Identification of the core network markers of four
cancers (28 proteins) - A brief review of our previous
methods
In our previous study [17], we used the systems biol-
ogy approach to study network markers of various can-
cers. Firstly, microarray data, PPI databases and PPI
interaction models were employed to construct the PPI
networks of normal and cancer cells by the maximum
likelihood parameter estimation method (see Additional
file 1). The AIC system order detection method (Addi-
tional file 2) was employed to prune false-positive PPIs
to obtain real PPI networks of normal and cancer cells:
in other words, we used the reverse engineering method
to construct the PPI networks of normal and cancer cells.
Then, the differential PPI network–obtained by contrast-
ing the cancer PPI network and normal PPI network–
was used to investigate PPI variations of each protein in
the differential PPI network due to carcinogenesis.
Finally, the carcinogenesis value (CRV) based on PPI var-
iations was proposed to evaluate the significance of each
protein for carcinogenesis in the differential PPI network.
Proteins with a significant CRV (p-value<0.01) were con-
sidered to be significant for the progress of the cancer.
The complete mathematical model is described as
follows.
After organizing the cancer microarray data and PPI
data, we used a PPI model, the maximum likelihood
parameter estimation method and a model order detec-
tion method together to prune each candidate PPIN by
the corresponding microarray data to approach the
actual PPIN of each cancer. Here, the PPIs of a target
protein i in the candidate PPIN can be depicted by the




αijxj[n] + ωi[n] (1)
where xi[n] represents the expression level of the tar-
get protein i for the sample n; xj[n] represents the expres-
sion level of the j-th protein interacting with the target
protein i for the sample n; αij denotes the association
ability between the target protein i and its j-th interactive
protein; Mi represents the number of proteins interact-
ing with the target protein i; and ωi[n] represents the
stochastic noise due to other factors or model uncer-
tainty. The biological meaning of equation (1) is that the
expression level of the target protein i is associated with
the expression levels of the proteins interacting with it.
Consequently, a protein association (interaction) model
for each protein in the protein pool can be built.
After constructing equation (1) for the PPI model of
each protein in the candidate PPIN, we used the
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maximum likelihood estimation method [20] to identify
the association parameters in (1) by microarray data as




αˆijxj(n) + wi(n) (2)
where αˆij is identified by the maximum likelihood
estimation method.
Once the association parameters for all proteins in the
candidate PPI network were identified for each protein,
the true protein associations were determined by pruning
the false positive PPIs. Akaike Information Criterion
(AIC) [20] and a Student’s t-test [21] were employed to
achieve model order selection for the pruning of false
positive protein associations in αˆij (see Additional file 2).
After the AIC order detection and use of the Student’s
t-test to determine p-values of αˆij , the false positive
PPIs αˆij in (2) were pruned away and only significant




αˆijxj(n) + wi’(n), i = 1, 2......M (3)
where Mi′ ≤ Mi denotes the number of true PPIs,
with the target protein i, i.e., a number of Mi −Mi ′ (or
false positives) are pruned in the PPIs of target protein
i. One protein by one protein (i.e., i = 1, 2, ...,M for all
proteins in refined PPIN in (3)) results in refined PPIN




























where the interaction matrix A denotes the PPIs.
If there is no PPI between protein i and protein j or it
is pruned by AIC order detection due to the false posi-
tive PPIs in the refined PPIN, then αˆij = 0. In general,
αˆij = αˆji , but if this is not the case, the larger one was
chosen as αˆij = αˆji to avoid the situation αˆij = αˆji . The
above PPIN construction method was employed to con-
struct the refined PPINs for cancer and non-cancer cells
of bladder, colorectal, liver, and lung cancer,
respectively.
The interaction matrices A of refined PPINs in (4) for
cancer and non-cancer cells of the four cancers were





















αˆkM1,N · · · αˆkMM,N
⎤
⎥⎦ (5)
where k = bladder cancer, colorectal cancer, liver can-
cer, and lung cancer; AkC and A
k
N denote the interaction
matrices of refined PPIN of the k-th cancer and non-
cancer, respectively; M is the number of proteins in the
refined PPIN. Therefore, the protein association model
for CPPIN and NPPIN in the k-th cancer and non-
cancer can be represented by the following equations












where k = bladder cancer, colorectal cancer, liver can-





2C · · · xkMC




2N · · · xkMN
]T
denote the vectors of expression levels;wKC(n) and
wKN(n) indicate the noise vectors of PPINs in the k-th
cancer and non-cancer cells, respectively.
The different matrix AkC - A
k
N of differential PPI net-




















αˆkM1,C − αˆkM1,N · · · αˆkMM,C − αˆkMM,N
⎤
⎥⎦ (7)
where k = bladder cancer, colorectal cancer, liver can-
cer, and lung cancer; dkij denotes the PPI variation
between the i-th protein and the j-th protein of differen-
tial PPI network by comparing CPPIN with NPPIN in
the k-th type of cancer; the matrix Dk indicates the dif-
ference in network structure between CPPIN and
NPPIN in the k-th type of cancer. In order to investigate
carcinogenesis from the difference matrix Dk between
CPPIN and NPPIN of the k-th cancer in (7), a score
named the carcinogenesis relevance value (CRV) was
presented to quantify the correlation of PPI variations of
each protein in Dk with the significance of carcinogen-
















∣∣∣ , and k = bladder cancer, colorectal
cancer, liver cancer, and lung cancer.
The CRVki in (8) quantifies the differential extent of
PPI variations of the i -th protein (the absolute sum of
the i-th row of Dk in (7)) and CRVk can differentiate
Wong et al. BMC Medical Genomics 2015, 8(Suppl 4):S4
http://www.biomedcentral.com/1755-8794/8/S4/S4
Page 4 of 23
CPPIN from NPPIN in the k-th cancer. In other words,
the CRVki in (8) could calculate the total PPI variations
of the i-th protein by comparing the network structure
differences between the cancer and non-cancer net-
works, which can be used to check which proteins are
involved with the k-th cancer.
In order to investigate which proteins are more likely
involved in the k-th cancer, we needed to calculate the
corresponding empirical p-value to determine the statis-
tical significance of CRVki . To determine the observed
p-value of each CRVki , we repeatedly permuted the net-
work structure of the candidate PPIN of the k-th type of
cancer as a random network of the k-th cancer. Each
protein in the random network of the k-th type of can-
cer will have its own CRV to generate a distribution of
CRVki for k = bladder, colorectal, liver, and lung cancer.
Although there was random disarrangement of the net-
work structure, the linkages of each protein were main-
tained, i.e., the proteins with which a particular protein
interacted were permuted without changing the total
number of protein interactions. This procedure was
repeated 100,000 times and the corresponding p-value
was calculated as the fraction of random network struc-
ture in which CRVki is at least as large as the CRV of
the real network structure. According to the distribu-
tions of CRVki of random networks, the CRV
k
i in (8)
with a p-value of less than or equal to 0.01 was regarded
as a significant CRV and the corresponding protein was
determined to be a significant protein in the carcinogen-
esis of the k-th cancer: a protein with a p-value > 0.01
was removed from the list of significant proteins in car-
cinogenesis (in other words, if the p-value of CRVki >
0.01, then the i-th protein was removed from CRVk in
(8) and the remainders in CRVk with p-values of CRVs
less than 0.01 were significant proteins of the k-th can-
cer). Based on the p-value of the CRVs for all proteins
( i = 1, 2, ...,M ) and the four types of cancer (k = blad-
der, colorectal, liver, and lung cancer), we generated
four lists of significant proteins (Additional file 3: Table
S1) for the cancers according to the CRV and the statis-
tical assessment of each significant protein in CRVk in
(8). As shown in Table S1, we found 107 significant pro-
teins in bladder cancer, 110 significant proteins in liver
cancer, 60 significant proteins in colorectal cancer, and
86 proteins in lung cancer. These proteins have signifi-
cant PPI changes between the CPPIN and NPPIN in the
carcinogenic process for their corresponding cancer and
we suspect that they may play important roles in carci-
nogenesis, warranting further investigation.
The intersection of these significant proteins in the
four cancers and their PPIs is known as the core
network markers, while the differences of these signifi-
cant proteins are the unique significant proteins of each
cancer and their PPIs in each of the cancers are known
as the specific network markers for each cancer. We
found that there were 28 significant proteins that could
be classified as a core network marker and 26, 4, 24,
and 13 significant proteins that were specific network
markers of bladder, colorectal, liver, and lung cancer,
respectively. The core network and specific network
markers for the cancers are described in our previous
paper [17]. This insight into the carcinogenic mechan-
isms of common core and specific network markers in
different cancers will be discussed in detail in the fol-
lowing section.
The 28 significant proteins in Figure 1(a) (see also
Table 1) are significant proteins shared by the four can-
cers, and these proteins and their PPIs form the com-
mon core network markers of these four cancers. The
significant proteins outside of these 28 are specific net-
work markers, distinct for each cancer. Finally, based on
these common core network markers and specific net-
work markers, we investigated the mechanisms behind
the carcinogenesis process with the help of databases
(for example, GO database [23], DAVID database
[24,25], and KEGG pathway database [26,27]) to find
multiple network targets for cancer therapy. Unlike con-
ventional theoretical methods that generate a single
mathematical model for a cancer network for detailed
theoretical analysis, ours is a systems biology approach
to cancer network markers based on real microarray
data through reverse engineering, theoretical statistical
methods, and data mining in combination with big data-
bases. These features made our method novel and
helped produce the significant findings of our paper.
The above paragraphs are adapted from our previous
study [17] to make this paper to be a complete paper.
Several scenarios to break down the cancer core network
In this study, we used several different approaches to break
down the cancer core network. This is the key feature of
this research, which confers it novelty. In contrast to tradi-
tional single target therapy, we used multiple-target cock-
tail therapy to attack common core network markers, i.e.,
to inhibit several key proteins simultaneously instead of
inhibiting only one single target. We assume that precisely
targeting the core network would reduce the activity of the
cancer. Based on this assumption, we believe that attacking
core network markers simultaneously will be more efficient
than attacking only one target. The first important problem
is how to choose the group of key proteins to target. The
first two novel approaches below to break down the cancer
core network are based on the systems biology approach
employed in our previous study [17]. We developed the
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third approach by performing pathway analysis using
Panther [28] and MetaCore (GeneGo Inc.) [29]. In addi-
tion, we used a ‘confusion pharmacophore model’ to
develop the fourth novel trial approach.
In the first approach, we chose the compounds with
highest docking scores for each of the 28 significant pro-
teins. Then we removed the redundant compounds, and
analyzed which compounds can target more than two pro-
teins simultaneously. The basic strategy is to minimize the
number of compounds necessary to target in order to
break down the core network. Since there are 28 proteins
in this core network, even choosing only one ligand to
inhibit each of these 28 proteins would necessitate
28 ligands, which may be unsuitable for wet-lab validation.
Figure 1 Core network marker and system flow chart. (1a) This is the PPI network of the 28 proteins of the core network marker of four
cancers. We see both ESR1 and BRCA1 are most highly connected with other proteins. (1b) We use the CADD method to target the 28 core
proteins obtained by previous systems biology method. We use both structure-based and ligand-based CADD with pathway and functional
analyses to develop 4 scenarios to break down the core network.
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In the second approach, we used the summation of
the CRVs (Table 2 and Table 3) as the criterion to
choose the key proteins to inhibit. In our previous
study, we showed that CRV quantifies the extent of a
protein’s association with other proteins, and thus it is
optimal to target proteins with the highest summation
of CRVs. This strategy depends on the cancer being tar-
geted; in the present study, we focused on the common
core network markers of the four cancers, so we chose
the highest summation of CRVs across the four cancers.
In the third approach, we employed many new and
valuable pathway analyses. Wet-lab cancer researchers
can choose the pathway they want to focus on as the
therapy target. There are many different combinations
dependent on different conditions of cancers, so we do
not list all the possibilities. Here, we demonstrate a sin-
gle example, and others can develop their own scenarios
following this example with the help of our docking
results. (Additional file 4: Table S2)
The fourth novel approach is to develop confusion
and individual pharmacophore models of core network
markers (28 proteins) to do virtual screening using the
compounds stored in the Life Chemical database.
We highlight the different approaches in this section,
because they form the crux of this study. Please see Fig-
ure (1b). In the following sections, we describe the
related methods necessary for each of the approaches.
More pathway and functional analyses
A. Panther
In our previous studies, we performed pathway analy-
sis using the DAVID database. Here, we expand on the
previous analysis by performing more pathway and func-
tional analyses in order to develop a more efficient strat-
egy for multiple target therapy. This approach will allow
us to accumulate more information on possible therapy
strategies. The 28 proteins comprising the cancer core
network markers were analyzed for their molecular
functions, molecular processes, and subcellular localiza-
tions by the PANTHER (Protein ANalysis THrough
Evolutionary Relationships) classification system [28].
PANTHER was designed to classify proteins (and their
Table 1. Structure information of 28 core proteins
No Protein PDB id Resolution[Å] Chains Length Lignd Full Name
1 BRCA1 4IFI 2.20 A 214 BAAT peptide Breast cancer type 1 susceptibility protein
2 CDK2 3QQK 1.86 A 306 X02 Cyclin-dependent kinase 2
3 CEBPB * CCAAT/enhancer-binding protein beta
4 CREBBP 4A9K 1.81 A, B 119 TYL CREB-binding protein
5 CTNNB1 3TX7 2.76 A 527 P6L Catenin (cadherin-associated protein), beta 1
6 CUL1 4F52 3.00 A, C 282 n.a. Cullin 1
7 CUL3 4EOZ 2.40 B, D 346 n.a. Cullin-3
8 EP300 4BHW 2.80 A, B 578 01K E1A binding protein p300
9 ESR1 1UOM 2.28 A 254 PTI Estrogen receptor 1
10 HDAC1 4BKX 3.00 B 482 n.a. Histone deacetylase 1
11 HDAC2 4LY1 1.57 A, B, C 369 20Y Histone deacetylase 2
12 HDAC4 2VQM 1.80 A 413 HA3 Histone deacetylase 4
13 IRAK1 * Interleukin-1 receptor-associated kinase 1
14 ISG15 3SDL 2.29 C, D 164 n.a. ISG15 ubiquitin-like modifier
15 KIAA0101 * KIAA0101
16 MDM2 4MDN 1.90 A 94 Y30 Mouse double minute 2 homolog
17 MYC 1NKP 1.80 A, D 88 n.a. V-myc myelocytomatosis viral oncogene homolog
18 PCNA 3WGW 2.80 A, B 261 T2B Proliferating cell nuclear antigen
19 PRKDC 3KGV 6.60 A-F, O, P-T, X-Y 4128 n.a. Protein kinase, DNA-activated, catalytic polypeptide
20 PSMA3 * Proteasome subunit alpha type-3
21 RB1 3POM 2.50 A, B 352 n.a. Retinoblastoma 1
22 SRC 2SRC 1.50 A 452 ANP Proto-oncogene tyrosine-protein kinase Src
23 TERF1 3BQO 2.00 A 211 TIN2 peptide Telomeric repeat-binding factor 1
24 TP53 1TSR 2.20 A, B, C 219 n.a. Tumor protein p53
25 TRAF2 1D0A 2.00 A-F 168 OX40L peptide TNF receptor-associated factor 2
26 UBC 4FJV 2.05 B, D 86 n.a. Ubiquitin C
27 XRCC6 1JEQ 2.70 A 609 n.a. X-ray repair cross-complementing 6
28 YWHAZ 4HKC 2.20 A 250 alpha-4 peptide 14-3-3 protein zeta/delta
*3D structures prepared by homology model, I-Tasser.
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genes) in order to facilitate high-throughput analysis. It
has a friendly user interface, you only need to input the
gene list and set up the parameters, you will get the
results you want. Please see Additional file 5: Figure
S5.1 and the PANTHER website [28]
B. MetaCore
MetaCore includes a manually annotated database of
gene interactions and metabolic reactions obtained from
the scientific literature, including the most newly
updated ones. The enrichment analysis of the biological
process was based on the hypergeometric distribution
algorithm and relevant pathway maps. The mathematical





















BRCA1 11.5863 6.8236 10.8636 12.5188 41.7923 UBC 496.3222
CDK2 16.7366 14.069 14.4739 9.942 55.2215 TP53 79.4445
CEBPB 5.2303 4.433 5.4262 7.2717 22.3612 KIAA0101 71.9887
CREBBP 12.0995 9.5856 11.5906 11.1892 44.4649 HDAC1 70.5646
CTNNB1 7.6796 9.5993 9.304 4.8015 31.3844 CDK2 55.2215
CUL1 13.2669 11.2802 5.5283 8.5044 38.5798 CUL3 53.8054
CUL3 13.0117 12.9519 16.3169 11.5249 53.8054 MYC 53.3347
EP300 12.1078 13.2218 8.3187 7.1278 40.7761 PCNA 52.9045
ESR1 5.6189 10.3758 6.3873 8.6696 31.0516 HDAC2 47.6069
HDAC1 19.2879 19.5736 11.7823 19.9208 70.5646 CREBBP 44.4649
HDAC2 11.0938 9.7752 18.9463 7.7916 47.6069 BRCA1 41.7923
HDAC4 5.8659 5.8397 9.7845 6.2225 27.7126 EP300 40.7761
IRAK1 4.1157 6.646 7.0177 5.1777 22.9571 CUL1 38.5798
ISG15 4.4856 6.0239 5.8124 4.943 21.2649 YWHAZ 35.9252
KIAA0101 15.8188 16.7663 19.1403 20.2633 71.9887 CTNNB1 31.3844
MDM2 4.5647 4.753 11.5648 6.2816 27.1641 ESR1 31.0516
MYC 13.0423 10.7821 20.0595 9.4508 53.3347 SRC 28.3907
PCNA 13.3217 15.1438 9.6282 14.8108 52.9045 TRAF2 27.7637
PRKDC 4.0781 5.9369 8.5589 5.6736 24.2475 HDAC4 27.7126
PSMA3 5.8022 7.7978 8.0875 5.2831 26.9706 MDM2 27.1641
RB1 6.8922 5.5531 5.9763 8.3205 26.7421 PSMA3 26.9706
SRC 8.8026 4.0767 9.1407 6.3707 28.3907 RB1 26.7421
TERF1 5.4642 4.9046 6.2595 8.0708 24.6991 XRCC6 25.7358
TP53 19.5883 18.7422 25.9329 15.1811 79.4445 TERF1 24.6991
TRAF2 9.2003 4.7703 7.365 6.4281 27.7637 PRKDC 24.2475
UBC 158.5321 137.284 80.3851 120.121 496.3222 IRAK1 22.9571
XRCC6 5.2871 9.5585 6.0231 4.8671 25.7358 CEBPB 22.3612
YWHAZ 8.7995 12.6421 7.9038 6.5798 35.9252 ISG15 21.2649
Table 3. (b) Top 5 ligands for the top 5 CRV proteins












719481 122.887 673172 126.112 655102 165.722 627865 134.685 680359 108.336
633409 114.187 695409 125.821 669588 164.036 625439 134.097 678636 101.875
672968 111.867 682236 117.725 407811 158.565 647638 125.505 669299 101.27
734999 111.578 695405 115.63 704564 148.676 2426 124.722 679065 101.006
688121 111.501 667504 114.326 698687 147.054 707841 117.076 376791 100.92
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foundation of MetaCore is shown in supplementary
materials.
More pathway and functional analyses are fundamental
to learning more about the hidden mechanisms of cancer
networks. So, to interpret the results for the third approach
in a meaningful way, this topic must be explained and
described beforehand. The novelty of this paper is in its
combination of systems biology with computer-aided drug
design. Our research opens many new directions for multi-
ple-target drug design; we describe only a portion of our
results in this paper, for illustrative purposes. Our results
clearly show that our approaches show great promise for
future research to target special pathways through the
design of drugs having multiple targets.
Metacore is also user-friendly software. The various man-
uals and training materials can be download from public
website [30,31], and due to the copyright concern, we do
not copy too many material here. Please follow the instruc-
tions in these manuals, and you can very well analysis. The
mathematical foundation of Metacore is shown in Addi-
tional file 6. Of course, the more deeply you understand the
underlying statistics meaning, you can do better analysis.
Protein and ligand structures
The following section illustrates the computer-aided drug
design (CADD) strategy applied to target the 28 common
core network proteins. The first through third
approaches need both the 3D structures of proteins and
ligands, while the fourth pharmacophore approach only
needs the structures of the ligands. The first thing we
need is thus the 3D structures of the proteins. At this
stage, 24 of them are available in the well-known PDB
database, and we can download them directly, while
there are four proteins (CEBPB, IRAK1, KIAA0101 and
PSMA3) whose 3D structures have not been solved at
this stage (Table 1). We used the NCI (46872 ligands)
and Life Chemical (31742 ligands) drug libraries with the
filter “anti-cancer”. The Developmental Therapeutics
Program NCI/NIH offers the NCI-60 cell line screening.
The users can download the 3D ligands (drugs) struc-
tures from the website, and after the virtual screening,
you can request them send you these drugs for free. Life
Chemical is a commercial company, you have to pay to
get these drugs [32]. All drug structures were prepared
and minimized by Discovery Studio 3.5 (DS3.5). People
seldom do the virtual screening on multiple targets since
it is computationally intense. We performed this work on
an IBM server with 160 cores and 1 TB of memory.
Homology model and binding site prediction
Proteins do not always have 3D structures available in
the PDB database. Since only amino acid sequence data
without corresponding structures were available for four
of the proteins targeted in our study (CEBPB, IRAK1,
KIAA0101 and PSMA3) we used homology modeling to
predict the structures for these proteins. Among many
famous software and webservers, the I-Tasser webserver
developed by Zhang et al. [33] is the most well-known
homology modeling webserver. We used this server to
perform homology modeling of our proteins of interest
that lacked available 3D structures. For some well-
studied protein targets, structures with embedded
ligands are available, so the exact binding site for the
docking experiments is known. However, binding site
information was unavailable for most proteins, so we
used the COACH webserver [34], also developed by
Zhang et al., to predict the binding sites. The detailed
binding site information is shown in Additional File 7.
I-TASSER and COACH are both user friendly webser-
ver. You only need to input the sequence of protein
residue into the I-TASSER, and set up the parameters, it
will give you the predicted 3D protein structures. Users
input the 3D protein structures into the COACH and
set up the parameters, and then it will give you the pre-
dicted binding sites (Additional file 5: Figure S5.2, S5.3).
Docking
After prepared the 3D structures of proteins and
ligands, and find out the binding site, we can perform
docking for virtual screening. We used DS 3.5 to per-
form docking simulations, and then ranked the docking
results based on LibDock score. We chose the top 20
compounds for further analysis, such as the construction
of pharmacophore models. The DS 3.5 is also user
friendly software, users can download the manual from
website, please see the example for parameter setting of
docking. Please see Additional file 5: Figure S5.4
Pharmacophore Model
A. HypoGen method and virtual screening
There are three stages in the generation of the Hypo-
Gen model: constructive phase, subtractive phase and
optimization phase. (1) Constructive phase: Active
ligands within a given range of the maximum activity are
chosen initially. The two most active ligands are used to
enumerate the pharmacophores. (2) Subtractive phase:
After the constructive phase, a database with a large
number of pharmacophore structures is generated. The
purpose of the subtractive phase is to identify the inactive
pharmacophores and eliminate them from the database.
(3) Optimization phase: The simulated annealing method
is used to modify the scoring function of each hypothesis
to be tested. After optimization, the HypoGen method
generates the top 10 hypotheses. This study is our first
attempt to combine systems biology with CADD. Phar-
macophore modeling is one of the most powerful
approaches in CADD. Here, we developed a novel proto-
type pharmacophore model, which is different from the
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traditional one. As mentioned above, this is a novel idea,
and the pharmacophore model is just a prototype: it will
require further modification in future studies. In tradi-
tional pharmacophore modeling, the IC50 value for each
drug under investigation is necessary, but our model
does not require them. Instead, we linearly transformed
LibDock scores to generate putative IC50 values, and
used these values to build the pharmacophore. We com-
bined the top three ligands for each of the 28 proteins to
make a ligand pool, and then used this ligand pool to
construct a common pharmacophore; this is qualitatively
different from building 28 individual pharmacophores.
We build the Hypogen model by the DS 3.5, and it is also
user friendly. However, to build a correct Hypogen model
is a time consuming work, you need to try the different
combination of compounds. For a skill expert with nor-
mal computational resource, it often needs at least one
month to build the correct model. We show the user
interface for detailed parameter setting for your refer-
ence. Please refer to Additional file 5 : Figure S5.5.
B. PharmaGist
PharmaGist is another method to construct ligand-
based pharmacophores. Because it does not require IC50
values of ligands [35], it is easier to construct pharmaco-
phores by PharmaGist than by the HypoGen model. For
each protein, we constructed one PharmaGist model:
these models can be used to do virtual screening in the
future. PharmaGist is also a user friendly webserver.
Please see Additional file 5: Figure S5.6.
Cocktail multiple-target strategy: A novel model
combined with systems biology and CADD
In summary, we used systems biology to construct the
common core network marker of four different cancers,
which contains 28 proteins as the house-keeping proteins
shared by the different cancers. Then we used the dock-
ing and pharmacophore methods to perform virtual
screening on these 28 core proteins and get the top com-
pounds for each protein. In contrast to traditional single
target methods, we suggest using a combination of the
top compounds to perform cell proliferation experi-
ments. We have provided an example for each of our
first three approaches. Our research provides a novel
direction for target therapy for cancers. Wet-lab biomedi-
cal scientists can combine the top ligands for each of the
28 core proteins based on their experimental conditions
and the pathways that they want to focus on. As an early
stage project, we have taken a conservative approach,
only using the NCI anti-cancer drug library. As these
drugs have proven anti-cancer activity, our cocktail of
multiple drugs can be expected to slightly or moderately
enhance the therapeutic effect under the right wet-lab
conditions. Collaboration with and input from wet-lab
experts would permit the modification and optimization
of our model, and the scope could expand to include
other drug libraries in the virtual screening.
Biological Experimental Validations
The detailed protocol for the biological experiment in
this Part, please refer to our previous work [36]. And
the results please refer to Additional file 8. Recently, our
team members who are part of wet-lab experiments
have found that: if we used more than one drug to
attack more than one target at the same time, it will
decrease the IC50 of the drug. Our team has shown that
if we used Gefitinib (Iressa) and L4 (one drug from the
LOPAC drug library) to inhibit Src and EGFR at the
same time, we achieve lower cell viability.
Results and Discussion
Review of the results of our previous methods
Our previous study identified 28 core proteins in the
common core network marker for four cancers [17].
These are the proteins intersecting between the four
cancers’ PPI networks with the top CRVs. Figure 1(a)
shows the PPI information of each common core net-
work marker. As stated previously, these 28 core pro-
teins could be responsible for the house-keeping
mechanisms of these four cancers, so using the mini-
mum possible number of ligands to target the maximum
possible number of the 28 proteins could be the most
efficient strategy to attack the cancers.
Several approaches to break the cancer core network
marker
a. We chose the top 20 compounds with the highest
docking scores for each of the 28 significant proteins.
Of a total of 560 ligands (Additional file 4: Table S2),
we found there were 13 ligands that target 2 or 3 pro-
teins simultaneously (Table 4(a)) after redundancy ana-
lysis. These 13 ligands combined 11 target proteins
(Table 5new 3(b)). We used the 13 ligands as the mini-
mum package for breaking the core network by inhibit-
ing these 11 proteins. While this does not target all 28
proteins, the main purpose here was to minimize the
number of ligands at this first stage trial. (As we have
said, this is the first trial of our primary model.) Of
course, according to our docking results of these 28 pro-
teins, there are thousands of possible drug combinations
that can be used based on different analysis methods as
per a given researcher’s scope. It is quite possible to
develop combinations to target all the 28 proteins based
on our docking results.
b. In our previous research, we observed the CRVs of
the 28 core proteins for each of the four cancers (Table 2).
In this study, we summed up the 4 CRVs for each of the
28 proteins. After ranking these summations, we listed the
top 5 CRV summations (Table 2), and suggested them to
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be the therapeutic targets for breaking cancer core net-
work marker. According to our previous systems biology
analysis, we believe that inhibiting proteins with the
highest CRVs is a highly efficient way to attack cancers. As
the first trial, our combination of proteins with the top 5
CRVs should simply be taken as a proof of concept: one
can develop combinations according to one’s particular
needs based on our CRVs.
c. We have also listed pathway analyses using Panther
and MetaCore on the core network proteins. Other
scientists can use this information to choose the path-
ways that they want to target, and then choose the best
combination of drugs from our virtual screening results.
For instance, from the pathway analysis results using
Panther (Table 6), researchers interested in targeting the
p53 pathway can choose between EP300, CREBBP,
HDAC1, HDA2, TRAF2, CDK2, MDM2, and TP53 as the
therapy targets. For the above scenario, researchers can
choose the top drugs from Additional file 4: Table S2.
MetaCore gives us more information for the purpose of
target therapy. The top three modules mapped to our 28
core proteins are listed in Table 7. Taking the first map/
module (DNA damage_ATM/ATR regulation of G1/S
checkpoint) as an example, we see CDK2, p53, Ubiquitin,
BRCA1, c-Myc, PCNA, and MDM2 are related to this
module. As above, we can use the drugs in Additional file
4 : Table S2 to choose the optimal combination of drugs
to attack this module.
More pathway and functional analysis
A. Panther
The results of Panther are shown in Figure 2 and
listed in Table 6. We see the 28 core network markers
hit many important cancer-related pathways, such as
p53, Wnt signaling, p53 feedback loops 2, apoptosis, etc.
As we have described above, this study is a prototype
model. Inhibition of the right proteins hitting the key
pathways is an important strategic consideration in real
clinical situations. Our results offer another reference
for doctors to design the best combination of multiple
inhibitors. In the future, using clinical data from doctors
will help us perform deeper analysis. These preliminary
results also could help us exclude pathways unrelated to
cancer at the first stage, such as those related to Hun-
tington’s disease, Alzheimer’s disease, etc.
B. MetaCore
The results of MetaCore analysis are described below.
We have described the top three maps/modules (Table 7).
(i) DNA damage_ATM/ATR regulation of G1/S
checkpoint (Figure 3): It is the highest scoring map (i.e.,
the map with the lowest p value). ATM/ATR regulates
both the checkpoints of the G1/S and S/G2. DNA
damage checkpoints pathways arrest or delay the pro-
gression of cell cycle in response to the DNA damage.
Eukaryotic cell cycle have four phases, G1 (G indicating
gap), S (Synthesis), G2 (Gap 2), and M (Mitosis), and
one outside, G0 (Gap 0) [37]. When DNA damage
Table 4. NCI drugs target more than one protein
NO. NCI Drug Protein Name LibDock Score
1 625439 KIAA0101 145.708
625439 HDAC1(4BKX) 134.097
625439 HDAC4(2VQM) 149.324
2 645378 CEBPB(2E_42) 158.637
645378 KIAA0101 140.103
3 668448 BRCA1(4IFI) 192.069
668448 PSMA3 166.516
4 668577 MYC(1NKP) 125.603
668577 PSMA3 180.11
5 682094 TERF1(3BQO) 123.287
682094 YWHAZ(4HKC) 182.534
6 687363 MYC(1NKP) 145.138
687363 YWHAZ(4HKC) 184.649
7 695175 TRAF2(1D0A) 101.267
695175 PSMA3 148.83
8 695409 TP53(1TSR) 125.821
695409 PSMA3 164.906
9 704565 KIAA0101 137.38
704565 HDAC4(2VQM) 153.564
10 719660 MYC(1NKP) 134.021
719660 YWHAZ(4HKC) 200.903
11 724305 CEBPB(2E_42) 167.724
724305 HDAC4(2VQM) 141.195
12 726771 BRCA1(4IFI) 142.956
726771 HDAC4(2VQM) 148.366
13 742856 MYC(1NKP) 140.093
742856 TP53(1TSR) 100.787
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occurs, the G1/S checkpoints will inhibit the initiation
of replication to prevent cells from entering the S phase.
They are related to two pathways of signal transduction,
to initiate and maintain the G1/S arrest, respectively
[37]. Jiri Bartek et al. discussed “The DNA damage
response in tumorigenesis and the treatment of cancer”
[38]. [The above description is directly cited from the
Metacore document.]
(ii) Transcription_P53 signaling pathway (Figure 4): It
is the second highest scoring map (i.e., the map with
the second lowest p-value). The Tumor protein p53,
also known as p53 ortransformation-related protein 53
(TRP53), acts a significant role in shielding the genome
integrity. While being activated, p53 will bind to the
enhancer/promoter regions of downstream target
genes. And then it regulates the transcription of these
genes, through which it initiates cellular processes that
responsible for lots of its tumor-suppressor related
functions [39]. It is not surprising that core network of
4 cancers are related to the p53 signaling pathway.
[The above description is directly cited from the Meta-
core document.]
Table 6. the pathway analysis results of Panther
Rank Pathway title Count Gene
1 p53 pathway 8 EP300,CREBBP,HDAC1,HDA2,TRAF2,CDK2,MDM2,TP53
2 Wnt signaling pathway 7 EP300,CREBBP,HDAC1,MYC,HDAC2,CTNN1,TP53
3 p53 pathway feedback loops 2 6 MYC,RB1,CTNNB1,CDK2,MDM2,TP53
4 Parkinson disease 4 YWHAZ, CUL1,PSMA3,SRC
4 Gonadotropin releasing hormone receptor pathway 4 EP300,CREBBP,CTNNB1, SRC
5 Huntington disease 3 EP300,CREBBP,TP53
6 Apoptosis signaling pathway 2 TRAF2,TP53
6 Angiogenesis 2 CTNNB1, SRC
6 P53 pathway feedback loops 1 2 MDM2, TP53
6 Cadherin signaling pathway 2 CTNNB1, SRC
6 Transcription regulation by bZIP transcription factor 2 EP300, CREBBP
6 TGF-beta signaling pathway 2 EP300, CREBBP
7 Interleukin signaling pathway 1 MYC
7 Alzheimer disease-presenilin pathway 1 CTNNB1
7 Integrin signalling pathway 1 SRC
7 Insulin/IGF pathway-protein kinase B signaling cascade 1 MDM2
7 Hypoxia response via HIF activation 1 CREBBP
7 Ubiquitin proteasome pathway 1 MDM2
7 p53 pathway by glucose deprivation 1 TP53
Please see their statistical distribution in Figure 2.
Table 7. Top three modules/maps given by Metacore
No Processes Map of core proteins
1 DNA damage_ATM/ATR regulation of G1/S checkpoint: It is the highest scoring map (i.e., the map
with the lowest p value). ATM/ATR regulates both the checkpoints of the G1/S and S/G2. DNA damage
checkpoints pathways arrest or delay the progression of cell cycle in response to the DNA damage.
Eukaryotic cell cycle have four phases, G1 (G indicating gap), S (Synthesis), G2 (Gap 2), and M (Mitosis),
and one outside, G0 (Gap 0).
CDK2, p53, Ubiquitin, BRCA1, c-Myc,
PCNA, MDM2
2 Transcription_P53 signaling pathway: It is the second highest scoring map (i.e., the map with the
second lowest p-value). The Tumor protein p53, also known as p53 ortransformation-related protein 53
(TRP53), plays a significant role in shielding the genome integrity. While being activated, p53 will bind
to the enhancer/promoter regions of downstream target genes. And then it regulates the transcription
of these genes, through which it initiates cellular processes that responsible for lots of its tumor-
suppressor related functions. It is not surprising that core network of 4 cancers are related to the p53
signaling pathway.
CDK2, p53, CBP, p300, Rb protein,
MDM2, Beta-catenin
3 DNA damage_BRCA1 as a transcription regulator: It is the third highest scoring map (i.e., the map
with the third lowest p-value). Activation of breast cancer susceptibility gene 1 (BRCA1) by DNA
damage occurs via activating the ataxia telangiectasia mutated serine/threonine protein kinase (ATM) or
serine/threonine-protein kinase ATR (ataxia telangiectasia and Rad3 related protein kinase). These
protein kinases can either directly or indirectly phosphorylate BRCA1 (by cell cycle checkpoint kinase 2
(Chk2)). BRCA1 acts a significant role in the DNA repair process by expediting cellular response upon
DNA repair. There are numerous DNA repair pathways (see map 427 Role of BRCA1 and BRCA2 in DNA
repair). We know that DNA repair is highly related to various cancers.
p53, ESR1 (nuclear), BRCA1, c-Myc,
PCNA, Rb protein
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(iii) DNA damage_Brca1 as a transcription regulator
(Figure 5): It is the third highest scoring map (i.e., the
map with the third lowest p-value). Activation of breast
cancer susceptibility gene 1 (BRCA1) by DNA damage
occurs via activating the ataxia telangiectasia mutated
serine/threonine protein kinase (ATM) [40] or serine/
threonine-protein kinase ATR (ataxia telangiectasia and
Rad3 related protein kinase) [41]. These protein kinases
can either directly or indirectly phosphorylate BRCA1
(by cell cycle checkpoint kinase 2 (Chk2) [42]). BRCA1
acts a significant role in the DNA repair process by
expediting cellular response upon DNA repair. There
are numerous DNA repair pathways (see map 427 Role
of BRCA1 and BRCA2 in DNA repair) [43]. We know
that DNA repair is highly related to various cancers.
[The above description is directly cited from the Meta-
core document.]
* The highest three scoring map (i.e., the map with the
three lowest p-value) is based on the enrichment distri-
bution sorted by the ‘Statistically significant maps’ set.
Experimental data from all files is linked to and visualized
on the maps as thermometer-like figures. Up-ward ther-
mometers are red and indicate up-regulated signals, and
down-ward (blue) ones indicate down-regulated expres-
sion levels of the genes. [The above description is directly
cited from the Metacore document.]
Statistical analysis results of the three maps are shown
in Table 7. These results also help us choose more sui-
table targets and exclude less suitable ones.
Protein and ligand structures
Table 1 shows detailed information of these 28 proteins
including protein name, PDB ID, resolution, chains,
length, ligands, and their full names. Most of these 3D
Figure 2 Pathway analysis by Panther. We see the 28 proteins of core network marker can hit many important cancer related pathways, such
as p53, Wnt signalling, p53 feedback loops 2, apoptosis, etc. As we have described above, this study is only a prototype model. By the Panther
analysis, we could know to inhibit the right proteins which hit the key pathways and is one of the important strategies in the real clinical
situation. This result offers another reference for doctors to design the best combination of multiple inhibitors. We will do more deep analysis in
the future if more clinical doctors could offer the clinical data to us. The preliminary results also could help us exclude the cancer-unrelated
pathways at the first stage, such as Hungtingon disease, alzeheimer, etc.
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structures were downloaded from the PDB database. 3D
structures of CEBPB, IRAK1, KIAA0101 and PRKDC
were constructed by homology modeling using I-TAS-
SER. We can see that many protein structures also con-
tained a ligand in a bound conformation. We used the
locations of these ligands within the target protein as
the docking site. Binding sites of proteins without
bound ligands were predicted using COACH.
Docking
Figure 6 Additional file 9 shows the docking pose of the
top compounds (i.e., those with the highest docking
score). Their docking scores ranged from 95 to 241. The
analysis also shows the key residues in ligand binding.
Our study is the first to perform high-throughput
multiple-protein docking, and this work requires large
computational resources. Due to space limitations,
we have not listed another table for these key residues.
The information could be useful for future drug design
and these top compounds could be considered as con-
trol ligands.
Pharmacophore
3D pharmacophore modeling is another powerful
method to perform virtual screening on large ligand
databases. It is as powerful as the docking method, and
is always more efficient than docking methods. For
example, the large ligands database ZINC [44] has more
than 200 million ligands. By calibrating the parameters
of the pharmacophore virtual screening, it is possible to
Figure 3 DNA damage_ATM/ATR regulation of G1/S checkpoint. It is the highest scoring map (i.e., the map with the lowest p value). ATM/
ATR regulates both the checkpoints of the G1/S and S/G2. DNA damage checkpoints pathways arrest or delay the progression of cell cycle in
response to the DNA damage. Eukaryotic cell cycle have four phases, G1 (G indicating gap), S (Synthesis), G2 (Gap 2), and M (Mitosis), and one
outside, G0 (Gap 0).
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virtually screen the whole ZINC database using our IBM
server with 160 cores. We have even performed virtual
screening for Src inhibitors. However, constructing a
proper HypoGen model is also very time-consuming. As
an initial study using a novel approach, we used relatively
unrestricted conditions to set up a rough HypoGen
model. It would be beneficial to do virtual screening on
another ligand database in the future.
Figure 7 Additional file 10 lists the total 54 ligands used
to construct the HypoGen pharmacophore model. We
present the structure of the pharmacophore in Figure 6
new, where NSC-625869 refers to the ligand in the NCI
library of anti-cancer drugs that was screened and
matched by this pharmacophore. The numerical results of
the HypoGen model are shown in Tables 8, 9, 10. After
having constructed this pharmacophore, we were able to
use it to screen against other ligand databases, such as the
Life Chemical database. Figure 7 and Table 11new show
the compounds in the Life Chemical database screened
and matched by this pharmacophore. Compared to the
HypoGen model, the pharmacophore model derived by
PharmGist is easier to obtain because PharmGist does not
require the IC50 values of the compounds for computa-
tion. We have listed the results in Figure 8 and Table 12.
Biological Experimental Validations
Drug combination- Gefitinib (Iressa) combine with L4
and N4 in three different cells. In the three cell lines,
Figure 4 Transcription_P53 signaling pathway. It is the second highest scoring map (i.e., the map with the second lowest p-value). The
Tumor protein p53, also known as p53 ortransformation-related protein 53 (TRP53), plays a significant role in shielding the genome integrity.
While being activated, p53 will bind to the enhancer/promoter regions of downstream target genes. And then it regulates the transcription of
these genes, through which it initiates cellular processes that responsible for lots of its tumor-suppressor related functions. It is not surprising
that core network of 4 cancers are related to the p53 signaling pathway.
Wong et al. BMC Medical Genomics 2015, 8(Suppl 4):S4
http://www.biomedcentral.com/1755-8794/8/S4/S4
Page 15 of 23
they show that combination drug always get a better
efficiency that only single Iressa. Please refer to Addi-
tional file 8. At this stage, we have only used a simple
pathway diagram to visualize the relationship between
EGFR and Src without a large-scale systems biological
analysis. These results gave us confidence that multiple
drugs attacking multiple targets will achieve better
results. Indeed, we have accumulated lots of similar
results.
Novel model combined with both systems biology and
CADD
· General demonstration: Our method has reversed the
normal procedure of CADD with the help of systems
biology. In the traditional CADD method, a single
validated target, such as Src, EGFR, and FAK, is used as
the protein target. The first step is usually virtual
screening by docking or the pharmacophore method.
The second step is to validate the top compounds from
virtual screening with ELISA or Western blot wet-lab
experiments. If they are found to bind to the target pro-
teins, then researchers could employ these ligands in
cell proliferation experiments. For our novel approach,
we choose the top compounds from several targets
simultaneously, and then perform the cell proliferations
experiment at the beginning. Our hypothesis is that
these drug cocktails would destroy the core network,
although we have not experimentally validated whether
each top compound binds to its corresponding target or
not
Figure 5 DNA damage_Brca1 as a transcription regulator. It is the third highest scoring map (i.e., the map with the third lowest p-value).
Activation of breast cancer susceptibility gene 1 (BRCA1) by DNA damage occurs via activating the ataxia telangiectasia mutated serine/
threonine protein kinase (ATM) or serine/threonine-protein kinase ATR (ataxia telangiectasia and Rad3 related protein kinase). These protein
kinases can either directly or indirectly phosphorylate BRCA1 (by cell cycle checkpoint kinase 2 (Chk2)). BRCA1 acts a significant role in the DNA
repair process by expediting cellular response upon DNA repair. There are numerous DNA repair pathways (see map 427 Role of BRCA1 and
BRCA2 in DNA repair). We know that DNA repair is highly related to various cancers.
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Figure 6 new 8- The hypogen pharmacophore model built by DS3.5. We show the distances between the pharmacophores. No. 625869 is
the drug in NCI anti-cancer library screened and matched by this pharmacophore.
Figure 7 new 9- Life-Chemical drugs screened out by Hypogen. These are the top ligands of Life-Chemical drug library screened by our
hypogen pharmacophore model. Please see Table 10 for the detailed descriptions of these mapping results.
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Table 8. Top pharmacophore description
Category Number of ligands IC50 range
(nM)
Feature Correlation
28 targets 54 2-50000 HBA, HBA, HY, RA 0.92
Table 9. Top 10 pharmacophore descriptions
Hypothesis Total cost ΔCost RMS Correlation (r) Features
1 211.414 33.787 0.583549 0.924995 HBA, HBA, HY, RA
2 211.745 33.456 0.599912 0.920410 HBA, HBA, HY, RA
3 212.295 32.906 0.606595 0.918758 HBA, HBA, HY, RA
4 212.530 32.671 0.609627 0.917975 HBA, HBA, HY, RA
5 213.564 31.637 0.641692 0.908625 HBA, HBA, HY, RA
6 213.870 31.331 0.651935 0.905497 HBA, HBA, HY, RA
7 214.412 30.789 0.669021 0.900153 HBA, HBA, HY, RA
8 215.039 30.162 0.690558 0.893115 HBA, HBA, HY, RA
9 215.282 29.919 0.694361 0.891929 HBA, HBA, HY, RA
10 215.758 29.443 0.713440 0.885327 HBA, HBA, HY, RA
* Null cost = 245.201; Fixed cost = 202.014; Configuration cost = 19.2545; ΔCost = Null cost - Total cost. All costs are in units of bits.
* HBA, hydrogen bond acceptor; HY, hydrophobic; RA, ring aromatic.
Table 10. Experimental and estimation values of IC50 for each of the 54 ligands
NCI Drug IC50 (nM) Error NCI Drug IC50 (nM) Error
Exp. Est. Exp. Est.
625869 2.0 2.4 1.2 669299 4792.2 5656.4 1.2
668448 66.3 142.2 2.1 641847 5026.9 4480.2 -1.1
698233 256.5 97.5 -2.6 669230 5282.5 4302.8 -1.2
668433 380.2 229.7 -1.7 657381 5358.4 4451.3 -1.2
737026 810.9 366.4 -2.2 643737 5376.8 4463.6 -1.2
654626 1377.0 1868.5 1.4 691369 5509.1 4822.7 -1.1
726771 1877.1 4272.0 2.3 627399 5527.5 4285.1 -1.3
717079 2067.7 4413.1 2.1 627727 5892.9 14154.0 2.4
674086 2234.0 4138.9 1.9 693235 6107.2 5310.1 -1.2
666346 2270.0 5579.5 2.5 675823 6377.0 5049.0 -1.3
740601 2627.9 4280.5 1.6 665675 6591.5 4380.4 -1.5
639795 2742.6 4358.1 1.6 295632 7254.4 4402.1 -1.6
673172 2823.0 4721.0 1.7 668373 7390.1 4343.3 -1.7
641236 2827.4 4418.8 1.6 749 7534.5 21062.2 2.8
76955 2836.7 4936.6 1.7 689447 8003.5 5397.9 -1.5
719481 3033.7 6903.6 2.3 202537 12700.6 21711.5 1.7
406433 3064.1 12371.9 4.0 639906 13142.7 5880.0 -2.2
683481 3344.0 4540.1 1.4 622153 14753.4 5742.3 -2.6
682236 3395.0 4677.1 1.4 622154 15831.2 4771.3 -3.3
661908 3469.7 4310.7 1.2 692400 50000.0 13059.1 -3.8
633409 3661.4 4382.2 1.2 687325 50000.0 14121.3 -3.5
672968 3845.3 4363.1 1.1 689530 50000.0 17997.5 -2.8
680359 4140.3 4290.9 1.0 691200 50000.0 21974.7 -2.3
76519 4334.6 3133.5 -1.4 684143 50000.0 32999.6 -1.5
702125 4732.2 4288.4 -1.1 683630 50000.0 40400.2 -1.2
678636 4732.9 12631.9 2.7 694265 50000.0 51746.7 1.0
682086 4770.1 4479.7 -1.1 695571 50000.0 61122.2 1.2
*Exp= Experimental value; Est=Estimation value by pharmacophore; Error=Est./Exp.
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· Time complexity versus space complexity: Our novel
approach is some kind like the problem of algorithm about
the time complexity and space complexity. To attack each
protein one by one is similar to the problem of time com-
plexity. This is the traditional strategy for single target drug
design. The traditional method needs to make sure the
drugs target to which protein exactly. In the language of
computer science, the traditional CADD method can only
do serial work but not parallelization work. By the help of
our systems biology approach, it turns the origin problem
from time complexity to space complexity. That is, you can
do parallelization attack to the multiple proteins simulta-
neously. The powerful of this parallelization attack is that
you can do various drugs combination trial at the short
time. When you get the better results, you can go back to
check each drug in the combination is useful for the pro-
teins individually or not. Honest to speak, there are possi-
ble too many uncertainties and inaccuracies in this model,
such as the network biomarkers predicted by our systems
biology approach, the binding site information, the phar-
macophore model or even the predicted 3D protein struc-
tures. However, due to the powerful of parallelization
attack (cocktail multiple drugs), it is possible to find the
useful cocktail combination under the situation of so many
uncertainties and inaccuracies. The problem of space com-
plexity we encounter now is that how many drugs we
could use at the same time. And this is our feature work.
· Welcome to asking for our help and cooperation:
We must emphasize that no matter how powerful of our
model, the most important thing is to combine with the
correct medical knowledge and intuition. After our model
gives so many possible combinations of drug, you have to
decide a set of best ones with your medical knowledge and
intuition to do the wet-lab experiment validation. We
already have a lot of these wet-lab results but not pub-
lished yet. Our teams also have abundant experience on
the single target drug design [45-47]. We have also built a
webserver of the systems biology model in the research
but not opened to public yet. It is welcome for your feed-
back and cooperation. You are welcome to modify the old
version source code of our systems biology model [48].
Please refer to Additional file 8.
· Novelty and expectation results in the future: Com-
bination drugs is not a novel idea [49,50]. To design com-
bination drugs by our systems biology and CADD
methods is a novel work. We expect many combination
drugs will be really useful by the help of model. We would
like to enhance and modify our model in the future.
Availability of this method
We are in the process of building a webserver to iden-
tify network biomarkers. At this stage, we can construct
the network on request. We also offer a working version
of the source code (Additional File 11), and the readers
can modify this version of source code to perform their
research experiments.
Conclusions
In this study, we combined systems biology with tradi-
tional computational-aided drug design to design drug
Table 11. The Life-Chemical ligands are virtually screened by the hypogen model
ID No. FitValue Estimate HBA_1 HBA_2 HY_3 RA_4
F0325-0146 6.580 4.599 1 1 1 1
F0289-0199 6.446 6.266 1 1 1 1
F0922-0370 5.935 20.327 1 1 1 1
F0012-0228 5.690 35.775 1 1 1 1
F0496-0019 5.623 41.719 1 1 1 1
F0737-0405 5.55006 49.3217 1 1 1 1
F0382-0020 5.53538 51.0174 1 1 1 1
F0325-0148 5.1207 132.555 1 1 1 1
F0737-0312 5.00395 173.442 1 1 1 1
F0725-0356 4.98991 179.137 1 1 1 1
F0301-0263 4.9208 210.04 1 1 1 1
F0473-0314 4.90716 216.74 1 1 1 1
F0922-0913 4.87165 235.207 1 1 1 1
F1601-0068 4.58408 456.055 1 1 1 1
F0463-0195 4.50862 542.605 1 1 1 1
F0866-0317 4.26226 956.832 1 1 1 1
F0537-0936 4.17732 1,163.54 1 1 1 1
F0180-0144 3.96884 1,880.45 1 1 1 1
F0922-0900 3.95736 1,930.82 1 1 1 1
Please see the mapping diagrams in Figure 11.
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cocktails to inhibit the 28 proteins that comprise the
common core network markers of four cancers. The
results of our previous study have led us to believe that
those proteins likely represent house-keeping proteins of
these four cancers. Wet-lab researchers could use the
cocktails of multiple drugs indicated by our analysis as
objects of study in experiments on treating the four can-
cers. Moreover, with the help of sensitivity analysis, we
Figure 8 new 10-PharmGist Pharmacophore Model. The pharmacophores for each of the 28 significant proteins built by PharmGist. Detailed
descriptions of these pharmacophores are in Tables 7-9. [*17:MYC(1NKP)’s pharmacophore could not be generated.]
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also found the most likely multiple drug targets for each
individual cancer.
Additional material
Additional file 1: Parameter Identification of PPI network by
Maximum Likelihood Method.
Additional file 2: Determination of significant protein associations
by AIC and Student’s t-test.
Additional file 3: The identified significant proteins in 4 cancers.
Additional file 4: Docking results for the top 20 ligands for the 28
proteins studied.
Additional file 5: new 6: User interface of commercial software and
free webserver.
Additional file 6: new 7: Mathematical foundation of Metacore.
Additional file 7: new 5: Binding site information for the 28
proteins.
Additional file 8: new 10: Biological experimental validation.
Additional file 9: new 8. Docking pose analysis of 28 core proteins.
The docking poses analysis shows the key residues of the proteins which
interact with the ligands. The analysis reveals more mechanisms to help
us design de novo drugs.
Additional file 10: new 9. 54 ligands used for developing the
Hypogen model.
Additional file 11: Source code (*.rar).
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Table 12. The pharmacophores descriptions of PharmGist
No. Protein PDB Score Features Spatial Features R H D A N P Chemicals Fig
1 BRCA1 4IFI 39.2 7 7 4 0 0 2 0 1 3 9-1
2 CDK2 3QQK 33.1 5 5 4 0 0 1 0 0 3 9-2
3 CEBPB 2E42 40.4 12 12 3 5 0 4 0 0 3 9-3
4 CREBBP 4A9K 29.9 5 5 1 0 2 2 0 0 9 9-4
5 CTNNB1 3TX7 23.7 3 3 2 0 0 1 0 0 7 9-5
6 CUL1 4F52 37.5 7 7 4 1 0 2 0 0 3 9-6
7 CUL3 4EOZ 25.7 5 5 2 0 0 3 0 0 3 9-7
8 EP300 4BHW 3.0 2 2 0 0 0 2 0 0 2 9-8
9 ESR1 1UOM 33.1 5 5 4 0 0 1 0 0 3 9-9
10 HDAC1 4BKX 26.5 4 4 3 0 0 0 0 1 4 9-10
11 HDAC2 4LY1 6.0 3 3 1 0 0 2 0 0 2 9-11
12 HDAC4 2VQM 34.0 7 5 0 0 2 5 0 0 3 9-12
13 IRAK4 2NRU 44.5 13 11 2 1 3 6 0 1 3 9-13
14 ISG15 3SDL 42.7 16 14 3 7 2 3 0 1 3 9-14
15 KIAA0101 26.5 4 4 2 0 1 1 0 0 3 9-15
16 MDM2 4MDN 36.0 5 5 3 0 0 2 0 0 6 9-16
17 MYC 1NKP 9-17
18 PCNA 3WGW 36.0 14 14 3 9 0 2 0 0 3 9-18
19 PRKDC 3KGV 36.7 7 7 3 0 3 1 0 0 3 9-19
20 PSMA3 14.7 3 3 1 0 0 2 0 0 3 9-20
21 RB1 3POM 36.4 4 4 3 0 0 1 0 0 9 9-21
22 SRC 2SRC 35.7 6 6 3 0 0 3 0 0 4 9-22
23 TERF1 3BQO 36.5 7 7 3 1 0 3 0 0 4 9-23
24 TP53 1TSR 33.8 6 6 4 1 1 0 0 0 3 9-24
25 TRAF2 1D0A 30.9 3 3 2 0 0 1 0 0 16 9-25
26 UBC 4FJV 41.6 10 9 3 1 1 5 0 0 3 9-26
27 XRCC6 1JEQ 141.1 22 22 0 0 10 12 0 0 3 9-27
28 YWHAZ 4HKC 34.9 3 3 3 0 0 0 0 0 12 9-28
Their pharmacophore diagrams are shown in Figure 7.
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